Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 5945Pancreatic Neoplasms 3561Carcinoma, Hepatocellular 3271Stomach Neoplasms 3056Colonic Neoplasms 2327Rectal Neoplasms 2191Esophageal Neoplasms 1800Liver Neoplasms 1246Neoplasms 1181Breast Neoplasms 1064Neoplasm Metastasis 870Carcinoma, Non-Small-Cell Lung 792Lung Neoplasms 744Cholangiocarcinoma 743Gastrointestinal Neoplasms 662Ovarian Neoplasms 630Esophageal Squamous Cell Carcinoma 584Prostatic Neoplasms 485Melanoma 457Biliary Tract Neoplasms 441Head and Neck Neoplasms 376Uterine Cervical Neoplasms 344Carcinoma, Renal Cell 329Gastrointestinal Stromal Tumors 326Adenocarcinoma Of Esophagus 315Sarcoma 303Barrett Esophagus 300Anus Neoplasms 284Gallbladder Neoplasms 283Endometrial Neoplasms 281

Interventions

camrelizumab 2apatinib 2Ramucirumab 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Gastrointestinal × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT02314117 2021-08-26

RAINFALL

Eli Lilly and Company

Phase 3 Completed
645 enrolled 22 charts
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡